Passage Bio (PASG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
Annual meeting scheduled for May 19, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by May 18, 2026.
Voting matters and shareholder proposals
Election of two Class III directors for three-year terms: Athena Countouriotis, M.D. and Sandip Kapadia.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation for named executive officers.
Advisory vote on the frequency of future say-on-pay votes.
Consideration of any other business that may properly come before the meeting.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and auditor ratification.
Latest events from Passage Bio
- Pending merger with Remix is vital as cash dwindles and operations wind down.PASG
Q2 2026 - Merger creates a leading RNA-focused biotech with REM-422 poised for ACC and AML impact.PASG
Investor presentation - Merger forms a biotech leader in RNA-targeted therapies with $100M in new funding.PASG
M&A announcement - All proposals passed, including annual advisory votes on executive compensation.PASG
AGM 2026 - Q1 2026 net loss narrowed, but cash shortfall drives strategic review and major cost cuts.PASG
Q1 2026 - PBFT02 gene therapy demonstrated durable biomarker and clinical benefits in FTD-GRN.PASG
Corporate presentation - PBFT02 gene therapy shows durable biomarker response and early disease-modifying potential in FTD-GRN.PASG
Corporate presentation - Shareholders will vote on directors, auditor, and executive pay, with strong governance and ESG focus.PASG
Proxy filing - Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning.PASG
TD Cowen 46th Annual Health Care Conference